MADRIGAL PHARMACEUTICALS, INC. Proceeds from Issuance of Secured Debt
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Proceeds from Issuance of Secured Debt of $350.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSecuredDebt · last filed 2026-02-19
- MADRIGAL PHARMACEUTICALS, INC. proceeds from issuance of secured debt for the quarter ending 2025-12-31 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from issuance of secured debt for the quarter ending 2024-12-31 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from issuance of secured debt for the quarter ending 2013-12-31 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from issuance of secured debt for the quarter ending 2013-09-30 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from issuance of secured debt for fiscal 2025 was $350.00M.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from issuance of secured debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from issuance of secured debt for fiscal 2023 was $65.00M.
- MADRIGAL PHARMACEUTICALS, INC. proceeds from issuance of secured debt for fiscal 2013 was $13.50M.
| Period end | Proceeds from Issuance of Secured Debt 3 month | Proceeds from Issuance of Secured Debt 6 month | Proceeds from Issuance of Secured Debt 9 month | Proceeds from Issuance of Secured Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $350.00M 10-K · filed 2026-02-19 | ||
| 2025-09-30 | $350.00M 10-Q · filed 2025-11-04 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $65.00M 10-K · filed 2026-02-19 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $0.00 derived: sum of 2 quarters · filed 2016-03-15 | $290.00K derived: sum of 3 quarters · filed 2016-03-15 | $13.50M 10-K · filed 2016-03-15 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $290.00K derived: sum of 2 quarters · filed 2014-11-06 | $13.50M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | $290.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | $13.50M 10-Q · filed 2014-08-06 | ||
| 2013-03-31 | $13.21M 10-Q · filed 2014-05-08 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-11 | $0.00 derived: sum of 2 quarters · filed 2014-03-11 | $0.00 derived: sum of 3 quarters · filed 2014-03-11 | $2.00M 10-K · filed 2014-03-11 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $0.00 derived: sum of 2 quarters · filed 2012-11-06 | $2.00M 10-Q · filed 2012-11-06 | $2.00M derived: sum of 4 quarters · filed 2013-03-14 |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $2.00M 10-Q · filed 2012-08-02 | $2.00M derived: sum of 3 quarters · filed 2013-03-14 | |
| 2011-03-31 | $2.00M 10-Q · filed 2012-05-03 | $2.00M derived: sum of 2 quarters · filed 2013-03-14 | ||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-14 | $15.00M 10-K · filed 2013-03-14 | ||
| 2010-09-30 | $15.00M 10-Q · filed 2011-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |